标题
Targeted Therapy in Melanoma and Mechanisms of Resistance
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 13, Pages 4576
出版商
MDPI AG
发表日期
2020-06-29
DOI
10.3390/ijms21134576
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting complex, adaptive responses in melanoma therapy
- (2020) Phil Cheng et al. CANCER TREATMENT REVIEWS
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
- (2020) Axel Hauschild et al. EUROPEAN JOURNAL OF CANCER
- Pan-cancer analysis of whole genomes
- (2020) NATURE
- A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
- (2020) Yangzi Tian et al. MEDICAL SCIENCE MONITOR
- Current Advances in the Treatment of BRAF-Mutant Melanoma
- (2020) Hima Patel et al. Cancers
- Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis
- (2020) Yosuke Yamamoto et al. Cancer Medicine
- Nothing Is yet Set in (Hi)stone: Novel Post-Translational Modifications Regulating Chromatin Function
- (2020) Jennifer C. Chan et al. TRENDS IN BIOCHEMICAL SCIENCES
- Many ways to resistance: How melanoma cells evade targeted therapies
- (2019) Ines Kozar et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- MITF—the first 25 years
- (2019) Colin R. Goding et al. GENES & DEVELOPMENT
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
- (2019) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
- (2019) Daniël A. Lionarons et al. CANCER CELL
- Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations
- (2019) Brian D. Lehmann et al. MOLECULAR CANCER RESEARCH
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Oncogenic BRAF: Past, Present, and Future
- (2019) Zaman et al. Cancers
- Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
- (2019) Khaliq et al. Cancers
- 1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
- (2019) J S Weber et al. ANNALS OF ONCOLOGY
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
- (2018) Jaquelyn N. Sanchez et al. DRUGS
- Ultraviolet light and melanoma
- (2018) Sarah Craig et al. JOURNAL OF PATHOLOGY
- Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
- (2018) Anthony W. Tolcher et al. MOLECULAR CANCER THERAPEUTICS
- BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
- (2018) Jacek Mackiewicz et al. Wspolczesna Onkologia-Contemporary Oncology
- A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor
- (2018) Jiawan Wang et al. Cancer Discovery
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
- (2018) Thomas Strub et al. Nature Communications
- 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
- (2018) P A Ascierto et al. ANNALS OF ONCOLOGY
- An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
- (2018) James Larkin et al. EUROPEAN JOURNAL OF CANCER
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
- (2018) Michael J. Vido et al. Cell Reports
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
- (2017) Xian Chan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The NF1 gene in tumor syndromes and melanoma
- (2017) Maija Kiuru et al. LABORATORY INVESTIGATION
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Pathways from senescence to melanoma: focus on MITF sumoylation
- (2017) J Leclerc et al. ONCOGENE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- BRAF inhibitors: resistance and the promise of combination treatments for melanoma
- (2017) Merope Griffin et al. Oncotarget
- Distinct histone modifications denote early stress-induced drug tolerance in cancer
- (2017) Abdullah Al Emran et al. Oncotarget
- Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma
- (2017) Antoneicka L. Harris et al. Oncotarget
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
- (2016) Michael P. Smith et al. CANCER CELL
- Neurofibromatosis type 1 (NF1 ) gene: Beyond café au lait spots and dermal neurofibromas
- (2016) Sirkku Peltonen et al. EXPERIMENTAL DERMATOLOGY
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
- (2016) Simona Caporali et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- RASopathy Gene Mutations in Melanoma
- (2016) Ruth Halaban et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR
- (2016) Goran Micevic et al. Cell Reports
- Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2016) Vidhu Sharma et al. eLife
- Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
- (2015) M. A. Wilson et al. CLINICAL CANCER RESEARCH
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
- (2015) Douglas B. Johnson et al. EUROPEAN JOURNAL OF CANCER
- The DNA methylation landscape of human melanoma
- (2015) Seung-Gi Jin et al. GENOMICS
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
- (2015) Lawrence N. Kwong et al. JOURNAL OF CLINICAL INVESTIGATION
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
- (2015) Michael Krauthammer et al. NATURE GENETICS
- Recurrent inactivating RASA2 mutations in melanoma
- (2015) Rand Arafeh et al. NATURE GENETICS
- In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells
- (2015) Jennifer Allouche et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
- (2015) Francesco Spagnolo et al. OncoTargets and Therapy
- BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
- (2015) Caterina Chiappetta et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
- (2015) Ryan B. Corcoran et al. Oncotarget
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- A stress-induced early innate response causes multidrug tolerance in melanoma
- (2014) D Ravindran Menon et al. ONCOGENE
- UV Signature Mutations
- (2014) Douglas E. Brash PHOTOCHEMISTRY AND PHOTOBIOLOGY
- Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway
- (2014) Alexander Gross et al. Targeted Oncology
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2014) David Blum et al. eLife
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600ETumors
- (2013) Meghna Das Thakur et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- The Akt signaling pathway
- (2012) SubbaRao V. Madhunapantula et al. CANCER BIOLOGY & THERAPY
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Molecular biology of melanoma
- (2012) Julie M. Swick et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Elucidating Distinct Roles for NF1 in Melanomagenesis
- (2012) Ophélia Maertens et al. Cancer Discovery
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Epigenetics in Alternative Pre-mRNA Splicing
- (2011) Reini F. Luco et al. CELL
- Genetic alterations of PTEN in human melanoma
- (2011) Almass-Houd Aguissa-Touré et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now